Trubion

Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel

Retrieved on: 
Wednesday, March 22, 2023
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Other Science, Science, Oncology, LLP, Interim, General counsel, Intellectual property, Senior counsel, Delhi Sikh Gurdwara Management Committee, Aristea, Cell, Associate, PwC, Acquisition, Trubion, Corporation, Sanofi, ACADIA, Growth, Seed, Therapy, Pharmaceutical industry, Management, Gorilla, Capstan, Finance, Cadence

Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.

Key Points: 
  • Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced the appointment of Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D. as General Counsel.
  • He most recently served as Chief Financial Officer at Aristea Therapeutics.
  • Most recently, he served as Interim Chief Executive Officer, General Counsel and Corporate Secretary at Silverback Therapeutics.
  • He has also served as Associate General Counsel and Head of Intellectual Property at Trubion Pharmaceuticals and as Chief Patent Attorney at Nastech Pharmaceutical Company (now Adhera Therapeutics).

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

Retrieved on: 
Wednesday, May 25, 2022
Biotechnology, Science, Health, Research, Â, Chemistry, Department, Medicinal chemistry, Cysteine, Lysine, Proteome, Trubion, Proteomics, Patient, Biology, Science, Therapy, Gilead Sciences, Computational chemistry, Terremoto, Industry, List of life sciences, Time, UCSF, Biotechnology, Toxicity, Third Rock Ventures, The Sun Sessions, Team America: World Police, Protein, HIV, Drug discovery, Cancer, Hepatitis, CEO, Fine chemical, Pharmaceutical industry, Incyte, Tetris

Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.

Key Points: 
  • Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
  • Terremoto is redefining what was once thought of as scientifically impossible with our well-defined platform approach and unrivaled team.
  • Terremoto leverages its covalent drug discovery and development engine to create highly targeted, small molecule medicines for a broad spectrum of severe diseases, including cancer.
  • Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy.

Gennao Bio Strengthens Board of Directors with Appointments of Peter Thompson, M.D., and Bradley Campbell

Retrieved on: 
Thursday, March 17, 2022
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Association, Therapy, Bristol Myers Squibb, MBA, Technology, University, Acquisition, Genzyme, Mathematics, Bio, Neurosurgery, Board of directors, Amicus Therapeutics, Â, Trubion, Organic acid, Duke University, Harvard Business School, Molecular biology, Affiliation, Cell, ARM, Board, National, Regenerative medicine, Company, Research, Chiron Corporation, Central Waqf Council, Drug development, University of Washington Department of Bioengineering, Becton, Dickinson and Company headquarters, Brown University, Public policy, Alpert Medical School, Sanofi, Pharmaceutical industry, Management

Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.

Key Points: 
  • Gennao Bio , a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointments of Peter Thompson, M.D., and Bradley Campbell to its Board of Directors.
  • On behalf of the Board and management, we welcome Peter and Bradley to the Gennao team.
  • Mr. Campbell is president and chief operating officer of Amicus Therapeutics and is also a member of its Board of Directors.
  • Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

Retrieved on: 
Friday, September 10, 2021

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekirolu to General Counsel.

Key Points: 
  • SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekirolu to General Counsel.
  • Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies, said Adam Simpson, Chief Executive Officer of Icosavax.
  • Ms. Bekirolu brings more than 15 years of experience advising pharmaceutical and biotechnology companies on a broad range of legal matters.
  • Prior to joining Icosavax, Ms. Bekirolu was Associate General Counsel at Seagen where she helped lead and build the legal affairs group as Seagen transformed into a multi-product, multinational company.

Fate Therapeutics Appoints Yuan Xu to its Board of Directors

Retrieved on: 
Wednesday, August 4, 2021
United Therapeutics, Trubion

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director.

Key Points: 
  • SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director.
  • Dr. Xu currently serves as an independent director on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO).
  • Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.

Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021

Retrieved on: 
Thursday, July 8, 2021
Pharmaceutical companies, Life sciences, Companies, Trubion, Regulus Therapeutics

WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled Novel Targets for Autoimmune Diseases, on Thursday, July 15, 2021 at 11:00 a.m.

Key Points: 
  • WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a virtual panel discussion at the William Blair Biotech Focus Conference 2021 titled Novel Targets for Autoimmune Diseases, on Thursday, July 15, 2021 at 11:00 a.m.
  • A live webcast of the panel discussion may be accessed through the Events page of the Investors section of Aclaris website, www.aclaristx.com .
  • Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options.
  • The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Life sciences, Immunology, Health care, Health sciences, Biotechnology, Immunogenicity, Biopharmaceutical, Autoimmunity, Trubion

The results were presented today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The results were presented today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Arcellxs proprietary binding domains are novel synthetic proteins engineered for reduced immunogenicity and designed to bind specific therapeutic targets.
  • CART-ddBCMA has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration.
  • Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

Retrieved on: 
Thursday, May 6, 2021
Life sciences, Biotechnology, Biology, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Trubion

b'SAN DIEGO, May 6, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of three new members to its Scientific Advisory Board (SAB).

Key Points: 
  • b'SAN DIEGO, May 6, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of three new members to its Scientific Advisory Board (SAB).
  • The new members of our SAB are all experts in Tscm cells, their metabolism and their use as therapeutics.
  • "\nPoseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

Retrieved on: 
Monday, May 3, 2021
Companies, Pharmaceutical companies, Trubion, Economy of the United States, Two River

b'Actuate Therapeutics, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases.

Key Points: 
  • b'Actuate Therapeutics, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases.
  • For additional information, please visit the company\'swebsite at http://www.actuatetherapeutics.com .\nLantern Pharma (Nasdaq: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR A.I.
  • platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics.
  • Lantern is currently developing four drug candidates and an ADC program across seven disclosed tumor targets, including two phase 2 programs.

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 9, 2021
Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Trubion

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur Sands, M.D., Ph.D., Nurixs chief executive officer, will participate and present at the following conferences in March:

Key Points: 
  • SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, todayannouncedthat Arthur Sands, M.D., Ph.D., Nurixs chief executive officer, will participate and present at the following conferences in March:
    Panel discussion: Targeted Protein Degradation Different Approaches, Same Goal?
  • The discussion and presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations .
  • An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.
  • Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases.